乌帕替尼在治疗中轴型脊柱关节炎中的作用。
The role of upadacitinib for the treatment of axial spondyloarthritis.
机构信息
Internal Medicine Residency Program, Boston University Medical Center, Boston, MA 02118, USA.
Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118, USA.
出版信息
Immunotherapy. 2023 Oct;15(15):1227-1237. doi: 10.2217/imt-2023-0032. Epub 2023 Sep 7.
Janus kinase inhibitors were recently approved for treatment of axial spondyloarthritis following clinical trials demonstrating benefit for symptom control. Upadacitinib treatment resulted in Assessment of SpondyloArthritis International Society 40 response improvement (defined as at least 40% improvement and an absolute improvement in global assessment of disease activity, patient assessment of back pain and other indices) in 45-52% of trial participants with axial spondyloarthritis. We review the data for efficacy and safety of upadacitinib in this patient population.
最近，在临床试验证明了对症状控制的益处后，Janus 激酶抑制剂被批准用于治疗轴性脊柱关节炎。Upadacitinib 治疗导致 45-52%的轴性脊柱关节炎试验参与者的脊柱关节炎国际协会 40 响应改善（定义为至少 40%的改善和疾病活动的整体评估、患者背部疼痛和其他指标的绝对改善）。我们回顾了 Upadacitinib 在这一患者人群中的疗效和安全性数据。
Zotero 插件